Clinical trial for Psychotic Disorders
Official title Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
ClinicalTrials.gov ID: NCT05445180
What this study is testing
- What it's testing
- The study aims to understand how the brain changes when people with psychosis stop using cannabis for four weeks.
- Who it's for
- The study is looking for adults with psychosis who use cannabis.
- What's involved
- Participants will be assigned to either stop using cannabis or continue using it. They will have brain scans (MRI) at the start and after 28 days.
- Time commitment
- The study lasts 28 days and requires brain scans at the beginning and end.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 to 80. Healthy volunteers may be eligible.
You may be able to join if
- Able to provide informed consent in English or French
- Heavy cannabis use (defined as weekly cannabis use for at six months) and/or DSM-5 diagnosis of CUD
- Have a Full-Scale IQ ≥ 75
- Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)
- Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)
You likely can't join if
- current SUD (other than CUD)
- MRI contraindications
- Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine
- Current suicidal or homicidal ideation
- Head injury requiring hospitalization or loss of consciousness \> 5 minutes
- Current medical diseases that requires hospitalization or regular monitoring
See the full eligibility criteria
- Able to provide informed consent in English or French
- Heavy cannabis use (defined as weekly cannabis use for at six months) and/or DSM-5 diagnosis of CUD
- Have a Full-Scale IQ ≥ 75
- Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)
- Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)
- Clinically stable (as measured by the PANSS-6, total score \<30) (psychosis patient arm only)
- current SUD (other than CUD)
- MRI contraindications
- Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine
- Current suicidal or homicidal ideation
- Head injury requiring hospitalization or loss of consciousness \> 5 minutes
- Current medical diseases that requires hospitalization or regular monitoring
- Being pregnant
- DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)
- Taking psychotropic medication
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.